Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHKA | P35790 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6649685 | 0.83 | CHKA (0.41) | CHKAFFAR1MAPTNPSR1HRH3 | |
| SCHEMBL14509644 | 0.82 | FFAR1 (0.49) | FFAR1 | |
| SCHEMBL6958004 | 0.80 | CHKA (0.40) | CHKAFFAR1MAPTNPSR1MAOA | |
| SCHEMBL16422833 | 0.79 | FFAR1 (0.43) | FFAR1MAPTHRH3LMNATDP1 | |
| SCHEMBL16422781 | 0.79 | FFAR1 (0.43) | FFAR1MAPTHRH3LMNATDP1 | |
| SCHEMBL16422779 | 0.79 | FFAR1 (0.43) | FFAR1MAPTHRH3LMNATDP1 | |
| SCHEMBL8120916 | 0.77 | FFAR1 (0.44) | FFAR1L3MBTL1 | |
| SCHEMBL1751544 | 0.77 | FFAR1 (0.48) | FFAR1HRH3 | |
| SCHEMBL4208284 | 0.76 | PIM1 (0.45) | MAPTPIM1CHRNB2CHRNA4 | |
| SCHEMBL27504809 | 0.76 | MEN1 (0.48) | CHKAFFAR1MAPTNPSR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8410100-B2 | Pteridinone derivatives as PI3-kinases inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-04-02 | — | — | US | disclosed |
| US-8410100-B2 | Pteridinone derivatives as PI3-kinases inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-04-02 | — | — | US | disclosed |
| US-8410100-B2 | Pteridinone derivatives as PI3-kinases inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-04-02 | — | — | US | disclosed |
| EP-2114945-B1 | PTERIDINONE DERIVATIVES AS PI3-KINASES INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2010-10-20 | — | — | EP | disclosed |
| US-20100099680-A1 | PTERIDINONE DERIVATIVES AS P13-KINASES INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-22 | — | — | US | disclosed |
| US-20100099680-A1 | PTERIDINONE DERIVATIVES AS P13-KINASES INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-22 | — | — | US | disclosed |
| US-20100099680-A1 | PTERIDINONE DERIVATIVES AS P13-KINASES INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-22 | — | — | US | disclosed |
| EP-2114945-A1 | PTERIDINONE DERIVATIVES AS PI3-KINASES INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008092831-A1 | PTERIDINONE DERIVATIVES AS PI3-KINASES INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-08-07 | — | — | WO | disclosed |
| EP-1953163-A1 | Pteridinone derivatives as PI3-kinases inhibitors | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2008-08-06 | — | — | EP | disclosed |
| EP-1953163-A1 | Pteridinone derivatives as PI3-kinases inhibitors | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2008-08-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099680-A1 | PTERIDINONE DERIVATIVES AS P13-KINASES INHIBITORS | PIK3CA, PDPK1, PIK3C3 | CHKA 348/4885FFAR1 1942/4885MAPT 4522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.